Menopause Drives Peak Female Suicide Rates — Hormones Are the Missing Link

Menopause is far more than the end of menstruation — it is a period of profound neuroendocrine disruption that can fundamentally alter a woman's mental health, cognition, relationships, and capacity to work. This narrative review synthesises existing evidence on the intersection of hormonal change and psychological wellbeing across the menopausal transition, with a particular focus on depression, anxiety, cognitive impairment, and suicide risk.

The biological case is compelling. Oestradiol modulates serotonergic pathways, and its decline or erratic fluctuation during perimenopause disrupts mood regulation. Progesterone is converted to allopregnanolone in the brain, a key modulator of GABA receptors involved in anxiety and mood stabilisation. Testosterone decline — often overlooked — contributes to low mood, fatigue, poor concentration, and hypoactive sexual desire disorder. The erratic hormonal environment of perimenopause, which can precede menopause by up to ten years, is identified as the period of greatest mental health vulnerability.

The review highlights alarming population-level data: UK female suicide rates from 2014–2023 peak in the 45–49 and 50–54 age cohorts, with the 50–54 group showing rates 48% higher than the preceding cohort. By contrast, the equivalent male peak in 2023 was only 1.4% higher than the previous group, suggesting a uniquely female midlife vulnerability. The authors identify several high-risk subgroups: women with prior depression (70% higher risk of hormonally related depression), those with premature ovarian insufficiency (POI, now estimated to affect up to 3.5% of women), those undergoing surgical menopause (double the rate of new-onset depression vs. controls), and women who abruptly cease HRT. A distinct clinical entity — hormonally related depression (HRD) — is described, characterised by retained insight into one's emotional deterioration, which paradoxically increases distress by creating a sense of powerlessness.

Despite NICE guidance recommending HRT as first-line treatment for perimenopausal mood disturbance, the review documents widespread gaps in clinical knowledge and prescribing confidence. CBT also has an evidence base and is recommended alongside HRT. The authors stress that management must be individualised, incorporating lifestyle modification, psychological support, and hormonal therapy tailored to symptom profile, medical history, and patient preferences. They note that women on average spend 38% of their lives post-menopause, and up to 12% of their lives in perimenopause — making optimised menopause care a matter of long-term public health, not merely quality of life.

The review calls urgently for expanded clinician training, greater research investment in women's hormonal health, and systemic recognition of menopause-related mental health as a distinct and treatable condition. The authors frame inaction not just as a clinical failure but as a societal one, with consequences extending to careers, families, and lives lost to suicide.